Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Q3 revenue falls 52% to $110.0 million; cuts 2026 revenue outlook

Negative Impact 4 of 5 earnings Written later

Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, down 52% from $231.1 million a year earlier, and a net loss of $32.7 million, compared with net income of $51.2 million in the prior-year quarter. The company lowered its full-year 2026 total revenue forecast to $600 million to $645 million from $645 million to $675 million, and its adjusted EBITDA forecast to $110 million to $140 million from $130 million to $150 million. Chief Financial Officer Rich Lindahl will retire effective December 31, 2026.

Key points

  • Q3 2026 total revenues were $110.0 million versus $231.1 million in Q3 2025; net loss per diluted share was $(0.64) versus $0.91 of net income per diluted share.
  • 2026 total revenue forecast revised to $600 million to $645 million, from $645 million to $675 million previously.
  • 2026 adjusted EBITDA forecast revised to $110 million to $140 million, from $130 million to $150 million previously.
  • Chief Financial Officer Rich Lindahl retires December 31, 2026; Frank Vargo, Treasurer, becomes interim CFO January 1, 2027.

The filing

CompanyEmergent BioSolutions Inc. (EBS)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:06 PM ET
Accession number0001367644-26-000110

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.